Cargando…

GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression

INTRODUCTION: The impact of reduction of systolic blood pressure or body weight on reduction of cardiovascular events during the treatment with glucagon-like peptide 1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter 2 inhibitors (SGLT2is) for type 2 diabetes is unclear. METHODS: We sear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Mei, Ding, Liang-Liang, Zhang, Miao, Lin, Jin-Hao, Wei, Xu-Bin, Huang, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509017/ https://www.ncbi.nlm.nih.gov/pubmed/32852698 http://dx.doi.org/10.1007/s13300-020-00912-z

Ejemplares similares

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
por: Yan, Hongle, et al.
Publicado: (2022)

LBODP046 Reduction In "Cardiovascular Death Or Hospitalisation For Heart Failure" With Sglt-2is Is Dependent On Weight Reduction: A Meta-regression Analysis
por: Ghosal, Samit, et al.
Publicado: (2022)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Does Gender Influence the Cardiovascular Benefits Observed with Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors? A Meta-Regression Analysis
por: Mahmoud, Ahmed N., et al.
Publicado: (2016)

Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
por: Pinto, Lana Catani, et al.
Publicado: (2015)

Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors
por: Yanagawa, Tatsuo
Publicado: (2018)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

FRI639 Effect Of Early Initiation Of GLP-1 RAs On Weight Reduction Among People With Type 2 Diabetes
por: Chinthammit, Chanadda, et al.
Publicado: (2023)

SAT-662 Effects of SGLT Inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis
por: Lim, Soo, et al.
Publicado: (2020)

The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression
por: Liang, Edwin F., et al.
Publicado: (2018)

Time point of nocturnal trough systolic blood pressure as an independent predictor of cardiovascular events
por: Zhu, Jing, et al.
Publicado: (2022)

GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
por: Mazzieri, Alessio, et al.
Publicado: (2023)

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
por: Imam, Ahmad, et al.
Publicado: (2023)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
por: Castellana, Marco, et al.
Publicado: (2019)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Lee, Heeyoung, et al.
Publicado: (2021)

The TRINITY Study: distribution of systolic blood pressure reductions
por: Sugimoto, Danny H, et al.
Publicado: (2013)

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
por: Sohn, Minji, et al.
Publicado: (2023)

Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention: A Meta-analysis and Meta-Regression
por: Hsu, Chia-Yu, et al.
Publicado: (2023)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
por: Ouchi, Motoshi, et al.
Publicado: (2018)

GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

Median bias reduction in random-effects meta-analysis and meta-regression
por: Kyriakou, Sophia, et al.
Publicado: (2018)

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
por: Uneda, Kazushi, et al.
Publicado: (2021)

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
por: Benham, Jamie L., et al.
Publicado: (2021)

Normal Systolic Blood Pressure at Presentation With Acute Ischemic Stroke Predicts Cardioembolic Etiology
por: Moores, Margaret, et al.
Publicado: (2020)

SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review
por: Janež, Andrej, et al.
Publicado: (2021)

Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol
por: Hussein, Humaira, et al.
Publicado: (2018)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
por: Du, Lixin, et al.
Publicado: (2022)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Prediction of cardiovascular events from systolic or diastolic blood pressure
por: Talebi, Atefeh, et al.
Publicado: (2022)

Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression
por: Musso, Giovanni, et al.
Publicado: (2020)

Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review
por: Zhou, Lingling, et al.
Publicado: (2023)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
por: Li, Chen, et al.
Publicado: (2022)

Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
por: Maiorino, Maria Ida, et al.
Publicado: (2021)

Meta‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF
por: Qiu, Mei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_052044q6sd2p6oqb9bbug179mq